Royalty 
Welcome,         Profile    Billing    Logout  
 27 Products   153 Diseases  27 Products   222 Trials   17735 News 
363 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Skytrofa (lonapegsomatropin-tcgd) / Ascendis
2021-004313-39: An extension study to check the safety of once weekly lonapegsomatropin when given for a long time in adults with growth hormone deficiency. Μία μελέτη επέκτασης για τον έλεγχο της ασφάλειας της άπαξ εβδομαδιαίως δόσης Lonapegsomatropin όταν χορηγείται για μεγάλο χρονικό διάστημα σε ενήλικες με ανεπάρκεια αυξητικής ορμόνης

Not yet recruiting
3
240
Europe
lonapegsomatropin drug product, ACP-011, Powder and solvent for solution for injection
Ascendis Pharma Endocrinology Division A/S, Ascendis Pharma Endocrinology Division A/S
Adult Growth Hormone Deficiency (AGHD) Ανεπάρκεια Αυξητικής Ορμόνης Ενηλίκων (AGHD), Lack of growth hormone in the body Έλλειψη αυξητικής ορμόνης στο σώμα, Diseases [C] - Hormonal diseases [C19]
 
 
enliGHten, NCT03344458 / 2017-003410-20: A Long-Term Trial Investigating Safety and Efficacy of TransCon hGH in Children With Growth Hormone Deficiency Who Have Completed a Prior TransCon hGH Clinical Trial

Completed
3
298
Europe, US, RoW
TransCon hGH
Ascendis Pharma A/S
Growth Hormone Deficiency, Pediatric, Endocrine System Diseases, Hormone Deficiency, Pituitary Diseases
02/23
02/23
foresiGHt, NCT04615273 / 2020-000929-42: A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency

Completed
3
264
Europe, Canada, Japan, US, RoW
Lonapegsomatropin, Placebo, Somatropin
Ascendis Pharma Endocrinology Division A/S
Growth Hormone Deficiency, Endocrine System Diseases, Hormone Deficiency
11/23
12/23
NCT05171855 / 2021-004313-39: A Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency

Completed
3
233
Europe, Canada, Japan, US, RoW
Lonapegsomatropin, ACP-011
Ascendis Pharma Endocrinology Division A/S, Ascendis Pharma Endocrinology Division A/S
Adult Growth Hormone Deficiency, Endocrine System Diseases, Hormone Deficiency
12/24
12/24
COACH, NCT06433557: A Phase 2 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of Navepegritide in Combination With Lonapegsomatropin in Children With Achondroplasia

Active, not recruiting
2
22
Europe
Combination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injections
Ascendis Pharma Growth Disorders A/S
Achondroplasia
09/25
09/27
NCT05690386: A Trial to Investigate Different Doses of Lonapegsomatropin Compared to Somatropin in Individuals With Turner Syndrome

Active, not recruiting
2
48
US
Lonapegsomatropin, Somatropin
Ascendis Pharma Endocrinology Division A/S
Turner Syndrome
12/24
12/27
SkyPASS, NCT05775523: A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin

Recruiting
N/A
500
US
No intervention
Ascendis Pharma Endocrinology Division A/S
Growth Hormone Deficiency
03/33
03/33
SkybriGHt, NCT05820672: A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA

Recruiting
N/A
900
US
No intervention
Ascendis Pharma Endocrinology Division A/S
Growth Hormone Deficiency
03/33
03/33
pelacarsen (AKCEA-APO(a)-LRx) / Novartis
2021-003059-41: A multicenter trial assessing the impact of lipoprotein(a) lowering with pelacarsen (TQJ230) on the rate of weekly lipoprotein apheresis sessions in patients with hyperlipoproteinemia(a) and established cardiovascular disease in Germany.

Not yet recruiting
3
46
Europe
Pelacarsen, TQJ230, Solution for injection in pre-filled syringe
Novartis Pharma AG, Novartis Pharma AG
Cardiovascular Disease, Apheresis, Diseases [C] - Cardiovascular Diseases [C14]
 
 
NCT06267560: Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD

Recruiting
3
400
US
TQJ230, pelacarsen, Placebo
Novartis Pharmaceuticals
Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease
03/27
03/27
NCT05305664: A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Rate of Weekly Lipoprotein Apheresis Sessions in Patients With Hyperlipoproteinemia(a) and Established Cardiovascular Disease in Germany

Completed
3
51
Europe
Pelacarsen (TQJ230) 80 mg s.c., TQJ230, Corresponding Placebo, Placebo
Novartis Pharmaceuticals
Hyperlipoproteinemia(a)
01/25
01/25
ADD-VANTAGE, NCT06813911: Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD

Recruiting
3
340
US
Pelacarsen, TQJ230, Placebo, Inclisiran
Novartis Pharmaceuticals
Atherosclerotic Cardiovascular Disease (ASCVD)
11/27
12/27
NCT06875973: Pelacarsen Roll-over Extension Program

Not yet recruiting
3
600
NA
Pelacarsen (TQJ230), TQJ230
Novartis Pharmaceuticals
Atherosclerotic Cardiovascular Disease
12/27
01/28
Lp(a)HORIZON, NCT04023552 / 2019-001076-11: Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD

Active, not recruiting
3
8323
Europe, Canada, Japan, US, RoW
TQJ230, Placebo, Placebo to match TQJ230
Novartis Pharmaceuticals
Cardiovascular Disease and Lipoprotein(a)
02/26
02/26
OLE, NCT05900141: An Open Label Extension () Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

Active, not recruiting
3
41
Europe
Pelacarsen, TQJ230
Novartis Pharmaceuticals
Hyperlipoproteinemia (a)
08/28
08/28
NCT05646381: A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis

Recruiting
2
502
Europe, Canada, US, RoW
Pelacarsen (TQJ230) 80mg, TQJ230, Matching placebo, Placebo
Novartis Pharmaceuticals
Aortic Stenosis
03/30
03/30
NCT07000695: Managed Access Programs for TQJ230, Pelacarsen

Available
N/A
NA
Pelacarsen, TQJ230
Novartis Pharmaceuticals
Atherosclerotic Cardiovascular Disease, ASCVD
 
 
TQJ230, NCT05548023: Time-trend Analysis of Clinical Characteristic and Outcomes in Patients With Unprotected Left Main Coronary Artery Disease Treated With PCI Over a 10-year Period

Active, not recruiting
N/A
500
RoW
The AngioliteTM Durable Fluoroacrylate Polymer-based Sirolimus-Eluting Stent
Chinese University of Hong Kong
Cardiovascular Diseases
12/24
02/25
Adlyxin (lixisenatide) / Sanofi
2014-002178-35: The renal effects of lixisenatide (a novel, gut-hormone based diabetes drug) and insulin glulisine (a common, wideley diabetes drug) Een onderzoek naar de werking van lixisenatide (een nieuw, op darmhormoon gebaseerd diabetes medicijn) en insuline glulisine (een veelgebruikt gangbaar diabetes medicijn) op de nierfunctie

Ongoing
4
40
Europe
Lixisenatide, Insulin glulisine, Lyxumia, Apidra, Lyxumia, Apidra
VU University Medical Center, VU University Medical Center, Sanofi-Aventis Netherlands B.V.
Type 2 Diabetes Mellitus Type 2 Diabetes
 
 
2016-001758-17: Lixisenatide Arterial Stiffness Trial

Ongoing
4
120
Europe
Lixisenatide (Lyxumia), Suspension for injection in pre-filled pen, Lyxumia
King's College London, Guy's and St Thomas' NHS Foundation Trust, Sanofi Aventis Limited
Type 2 diabetes, Diabetes, Diseases [C] - Hormonal diseases [C19]
 
 
ChiCTR2000037907: Effects of DPP-4 inhibitors on health-related quality of life in patients with type 2 diabetes

Not yet recruiting
4
600
 
DPP-4 inhibitors (including sitagliptin, sitagliptin, vildagliptin, linagliptin, alogliptin) ;GLP-1 receptor agonists (including exenatide, liraglutide, benaglutide, lixisenatide) ;SGLT-2 inhibitor (including dapagliflozin, empagliflozin, canagliflozin)
Shanghai Minhang Hospital; Shanghai Minhang Hospital, 2019 Shanghai Health Commission Research Project
Type 2 diabetes
 
 
NCT05804513: The Effect of Lixisenatide on the Effect of Pituitary Hormones

Recruiting
4
10
Europe
Placebo, Sodium chloride 0.9% solution, Lixisenatide 10 micrograms (50 micrograms/ml in 3 ml) Pen Injector, Lyxumia
University of Tartu, Tartu University Hospital
Healthy, Type 1 Diabetes
10/23
12/23
NCT06449235: Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh

Not yet recruiting
4
938
RoW
Omarigliptin, Sulphonylureas, Metformin, Other DPP4-i, Thiazolidinediones, Alpha-Glucosidase Inhibitor, Glucagon-Like Peptide-1, Receptor Agonists (GLP1RA), SGLT2 inhibitors
Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders, Pi Research and Development Center, Acme Laboratories Ltd.
Type2diabetes
04/25
06/25
2013-002259-14: The LIXI trial is aiming to recruit individuals with type 1 diabetes who are using insulin to control their disease. The trial is investigating whether a daily injection of a newly-licenced drug called lixisenatide, taken alongside a person\'s usual insulin medication can improve blood sugar levels after meals.

Ongoing
2
33
Europe
Lixisenatide 10 micrograms, Lixisenatide 20 micrograms, N/A, Lyxumia, Lyxumia
University of Oxford, Aventis Pharma Limited (Sanofi)
Type 1 diabetes mellitus
 
 
NCT02244164: Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.

Terminated
N/A
5
Europe
Incretinomimetics, - exenatide (Byetta®), - liraglutide (Victoza®), - lixisenatide (Lyxumia®), - exenatide extended-release (Bydureon®)., DPP-4 inhibitors, - sitagliptine (Januvia®), - vildagliptine (Galvus®), - saxagliptine (Onglyza®), - linagliptine (Trajenta®).
Erasme University Hospital
Type 2 Diabetes, Incretinomimetics, Pancreas
02/23
02/23
SEVERAL, NCT05136287: SEMAGLUTIDE VERSUS GLP-1 RECEPTOR AGONISTS. EFFECTIVENESS , SAFETY AND QUALITY OF LIFE IN PATIENTS WITH DIABETES MELLITUS 2. OBSERVATIONAL, PROSPECTIVE AND MULTICENTER STUDY. STUDY.

Completed
N/A
140
Europe
GLP-1 receptor agonist
Jose Seijas Amigo
Weight Loss, Diabetes Mellitus, Type 2, Quality of Life, Safety Issues
11/23
01/24
CER-4-T2D, NCT05220917: Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study

Active, not recruiting
N/A
781430
US
SGLT2 inhibitor, CANAGLIFLOZIN, CANAGLIFLOZIN/METFORMIN HCL, DAPAGLIFLOZIN PROPANEDIOL/METFORMIN HCL, DAPAGLIFLOZIN PROPANEDIOL, EMPAGLIFLOZIN, EMPAGLIFLOZIN/METFORMIN HCL, ERTUGLIFLOZIN PIDOLATE/METFORMIN HCL, ERTUGLIFLOZIN PIDOLATE, EMPAGLIFLOZIN/LINAGLIPTIN, EMPAGLIFLOZIN/LINAGLIPTIN/METFORMIN HCL, DAPAGLIFLOZIN PROPANEDIOL/SAXAGLIPTIN HCL, ERTUGLIFLOZIN PIDOLATE/SITAGLIPTIN PHOSPHATE, DPP-4 inhibitor, ALOGLIPTIN BENZOATE/METFORMIN HCL, ALOGLIPTIN BENZOATE, ALOGLIPTIN BENZOATE/PIOGLITAZONE HCL, SAXAGLIPTIN HCL, SAXAGLIPTIN HCL/METFORMIN HCL, LINAGLIPTIN, LINAGLIPTIN/METFORMIN HCL, SITAGLIPTIN PHOSPHATE/METFORMIN HCL, SITAGLIPTIN PHOSPHATE, SITAGLIPTIN PHOSPHATE/SIMVASTATIN, GLP-1RA, INSULIN DEGLUDEC/LIRAGLUTIDE*, INSULIN GLARGINE, HUMAN RECOMBINANT ANALOG/LIXISENATIDE*, LIXISENATIDE, LIRAGLUTIDE, DULAGLUTIDE, SEMAGLUTIDE, ALBIGLUTIDE, EXENATIDE MICROSPHERES, EXENATIDE, 2nd generation SU, PIOGLITAZONE HCL/GLIMEPIRIDE, ROSIGLITAZONE MALEATE/GLIMEPIRIDE, GLIPIZIDE/METFORMIN HCL, GLYBURIDE,MICRONIZED, GLYBURIDE/METFORMIN HCL, GLIMEPIRIDE, GLYBURIDE, GLIPIZIDE
Brigham and Women's Hospital, Patient-Centered Outcomes Research Institute, VA Boston Healthcare System, McGill University
Cardiovascular Events, Type2 Diabetes, Renal Disease
07/24
07/24
omecamtiv mecarbil (AMG 423) / Amgen, Servier
2020-003057-30: Omecamtiv Mecarbil Post-trial Access Protocol for Subjects Completing Study 20110203 GALACTIC-HF

Not yet recruiting
3
1286
Europe
Omecamtiv mecarbil, AMG 423, Modified-release tablet
Amgen Inc., Amgen Inc.
Chronic heart failure with reduced ejection fraction, Chronic Heart Failure, Diseases [C] - Cardiovascular Diseases [C14]
 
 
COMET-HF, NCT06736574: Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

Recruiting
3
1800
US
Omecamtiv Mecarbil (OM), Placebo
Cytokinetics
Heart Failure, Heart Failure With Reduced Ejection Fraction
09/27
12/27
Tysabri (natalizumab) / Biogen, Royalty
2007-007394-22: The role of white and grey matter and meningeal inflammation in multiple sclerosis (MS) and clinically isolated syndromes (CIS) as quantified using [(11)C](R)-PK11195 positron emission tomography (PET) scanning

Ongoing
4
10
Europe
Tysabri, Tysabri, Tysabri
Imperial College London
Multiple Sclerosis
 
 
2013-004626-28: Aivojen mikroglia-solujen aktivaation yhteys MS-tautiin

Ongoing
4
60
Europe
beetainterferoni -1a, Fingolimodi, REBIF, Gilenya, Avonex, Betaferon, Copaxone, Tysabri, Lemtrada, REBIF, Gilenya, Avonex, Betaferon, Copaxone, Tysabri, Lemtrada
Turku University Hospital, Novartis Pharma
Multiple sclerosis MS-tauti
 
 
2016-000345-31: Reduce the number of natalizumab infusions in patients with multiple sclerosis Verminderen van het aantal giften van natalizumab bij patiënten met multiple sclerose

Ongoing
4
60
Europe
natalizumab, Solution for infusion, tysabri
VU medical center, de Hersenstichting
multiple sclerosis multiple sclerose, MS MS, Diseases [C] - Nervous System Diseases [C10]
 
 
2017-002634-24: MultipleMS – a study with the aim to accelerate personalised medicine in multiple sclerosis. MultipleMS - en studie med syftet att utveckla precisionsmedicin för multipel skleros.

Ongoing
4
150
Europe
Infusion, Capsule, Tablet, Injection, Mabthera, Tysabri, Tecfidera, Gilenya, Copaxone, Betaferon, Extavia, Avonex, Rebif, Plegridy, Lemtrada, Aubagio
Karolinska Institutet, Department of Clinical Neuroscience, Karolinska Institutet
Newly diagnosed patients with Clinically Isolated Syndrome (CIS) and multiple sclerosis (MS) -both relapsing remitting and primary progressive), Multiple sclerosis (MS) is an autoimmune disorder of the central nervous system (CNS), characterized by repeated episodes of inflammation in the CNS leading to various neurological symptoms., Diseases [C] - Nervous System Diseases [C10]
 
 
2013-002433-38: Essai visant à tester la différence d’efficacité du Natalizumab, versus le fingolimod, 2 médicaments pour le traitement de la sclérose en plaques

Not yet recruiting
4
500
Europe
natalizumab, fingolimod, Concentrate for solution for infusion, Capsule, TYSABRI, GILENYA
CHU de Toulouse, FP7 Health Innovation-1
Sclérose en plaques, Sclérose en plaques, Diseases [C] - Nervous System Diseases [C10]
 
 
2019-002566-13: Personalizing the treatment with natalizumab in patients with multiple sclerosis

Not yet recruiting
4
300
Europe
natalizumab, Solution for infusion, Tysabri
Amsterdam University Medical Center, Innovatiefonds Zorgverzekeraars, Stichting MS Research, de Hersenstichting
Relapsing remitting multiple sclerosis, Multiple sclerosis (MS), Diseases [C] - Nervous System Diseases [C10]
 
 
NCT04048577: A Pilot Study to Characterize the Biological Effect of a Pre-planned 12 Week Dose Interruption of Natalizumab

Recruiting
4
10
US
Dosing Interruption of Natalizumab, Dosing Interruption of Tysabri
Berkovich, Regina MD, PhD Inc., Biogen, Cedars-Sinai Medical Center
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
11/21
12/21
NAPPREMS, NCT03046251: Natalizumab in Preventing Post-partum Relapses in Multiple Sclerosis

Completed
4
30
US
Natalizumab
State University of New York at Buffalo
Multiple Sclerosis
12/23
12/23
NCT05532163: A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)

Terminated
4
1
Europe
Natalizumab, Tysabri, BG00002
Biogen
Multiple Sclerosis, Relapsing-Remitting
10/23
10/23
NTZ2TTY, NCT02769689: Methylprednisolone During the Switch Between Natalizumab and Fingolimod

Recruiting
4
56
Europe
Methylprednisolone, Placebo, natalizumab (NTZ), fingolimob (FTY)
University Hospital, Clermont-Ferrand
Multiple Sclerosis
06/24
07/24
NCT04178005: Cladribine Tablets After Treatment With Natalizumab (CLADRINA)

Active, not recruiting
4
40
US
Cladribine, Mavenclad
University of Texas Southwestern Medical Center, EMD Serono
Multiple Sclerosis
08/26
12/26
NCT05177718: Natalizumab and Chronic Inflammation

Terminated
4
1
US
Natalizumab 300 MG in 15 ML Injection
Vanderbilt University Medical Center, Biogen
Multiple Sclerosis
04/23
04/23
SUPERNEXT, NCT04225312: Personalized Extended Interval Dosing of Natalizumab in Relapsing Remitting Multiple Sclerosis

Enrolling by invitation
4
300
Europe
Personalized extended interval dosing of natalizumab, EID, Standard interval dosing, SID
Amsterdam UMC, location VUmc, Stichting MS Research, Innovatiefonds Zorgverzekeraars, Stichting Treatmeds
Relapsing Remitting Multiple Sclerosis
03/25
03/25
DELIVER-MS, NCT03535298: Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS

Active, not recruiting
4
800
Europe, US
Early Highly Effective Therapies Group, Lemtrada (alemtuzumab), Ocrevus (ocrelizumab), Tysabri (natalizumab), Rituxan (rituximab), Kesimpta (ofatumumab), Briumvi (ublituximab), Escalation Therapies Group, Betaseron (beta interferon), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Extavia (beta interferon), Gilenya (fingolimod), Glatopa (glatiramer acetate), Plegridy (beta interferon), Rebif (beta interferon), Tecfidera (dimethyl fumarate), Avonex (beta interferon), Mavenclad (cladribine), Mayzent (siponimod), Vumerity (diroximel fumarate), Zeposia (ozanimod), Bafiertam (monomethyl fumarate), Ponvory (ponesimod)
The Cleveland Clinic, University of Nottingham
Multiple Sclerosis, Relapsing-Remitting
07/27
09/30
ACTRN12605000769684: An Open-label, Multicenter, Extension Study to Evaluate the Safety and Tolerability of Natalizumab Following Re-Initiation of Dosing in Multiple Sclerosis Subjects Who Have Completed Study C-1801 or C-1802 and a Dosing Suspension Safety Evaluation

Not yet recruiting
3/4
900
 
Biogen Idec, Biogen Idec, Elan Pharmaceuticals
Multiple Sclerosis
 
 
ACTRN12616000617460: What is the safety and effectiveness, acceptability and cost of flexible delivery of natalizumab (Tysabri (Registered Trademark)) by nurses for people with multiple sclerosis?

Active, not recruiting
3
50
 
Dr Janakan Ravindran, Biogen Australia and New Zealand
relapsing-remitting multiple sclerosis (MS)
 
 
2018-001292-21: Disease modifying therapies withdrawal in inactive Secondary Progressive Multiple Sclerosis patients older than 50 years Arrêt des traitements de fond à visée immunologique chez les patients de plus de 50 ans ayant une sclérose en plaques secondairement progressive

Not yet recruiting
3
250
Europe
AVONEX, BETAFERON, EXTAVIA, REBIF, PLEDIGRY, COPAXONE, AUBAGIO, TECFIDERA, GILENYA, TYSABRI, IMUREL, NOVATREX, CELLCEPT, ENDOXAN, L03 AB 08, Concentrate for solution for injection, Powder for solution for injection, Solution for injection, Solution for injection in pre-filled syringe, Tablet, Capsule, Concentrate for solution for infusion
CHU de Rennes, CHU de Rennes
Secondary Progressive Multiple Sclerosis Sclérose en plaques secondairement progressive, Secondary Progressive Multiple Sclerosis Sclérose en plaques secondairement progressive, Diseases [C] - Nervous System Diseases [C10]
 
 
NOVA, NCT03689972 / 2018-002145-11: A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration

Completed
3
585
Europe, Canada, US, RoW
Natalizumab, BG00002
Biogen
Multiple Sclerosis, Relapsing-Remitting
01/23
07/23
NCT05265728: A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis

Terminated
3
21
Japan
Natalizumab, BG00002
Biogen
Multiple Sclerosis, Relapsing-Remitting
01/24
05/24
BEAT-MS, NCT04047628: Best Available Therapy Versus Autologous Hematopoetic Stem Cell Transplant for Multiple Sclerosis

Recruiting
3
156
US
Autologous Hematopoietic Stem Cell Transplantation, AHSCT, Best Available Therapy (BAT), natalizumab (Tysabri®), alemtuzumab (Campath®, Lemtrada®), ocrelizumab (Ocrevus®), rituximab (Rituxan®), cladribine (Mavenclad®), ofatumumab (Kesimpta®), ublituximab (BRIUMVI™)
National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network (ITN), Blood and Marrow Transplant Clinical Trials Network, PPD DEVELOPMENT, LP, Rho Federal Systems Division, Inc.
Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
10/26
10/29
MIST, NCT03133403 / 2012-004165-41: Hematopoietic Stem Cell Therapy for Inflammatory Multiple Sclerosis Failing Alternate Approved Therapy

Recruiting
2/3
5
Europe
Tecfidera (BG12), Gilenya, fingolimod, Tysabri®, natalizumab, Avonex/Betaseron/Copaxone/Rebif, (Avonex®, Betaseron®, Copaxone®, Rebif®), Hematopoietic stem cell transplantation (HSCT)
Sheffield Teaching Hospitals NHS Foundation Trust
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
12/21
12/21
2010-023560-40: Blood stem cell transplantation for patients with relapsiong-remitting multiple sclerosis, in whom standard treatment has failed. Blodstamcellstransplantation för patienter med skovvis förlöpande MS (multipel sklerosis), där standardbehandling givit otillräcklig effekt.

Ongoing
2
120
Europe
, Powder for solution for injection, Powder for infusion*, Solution for injection, Powder and solvent for dispersion for injection, Tysabri, Sendoxan, Thymoglobuline, Neupogen, Solu-Medrol
Uppsala l�ns landsting
Relapsing-remitting multiple sclerosis
 
 
2014-000675-13: Natalizumab (Tysabri®) for the treatment of anti-Hu associated paraneoplastic neurological syndromes Natalizumab (Tysabri®) voor de behandeling van paraneoplastische neurologische syndromen met anti-Hu antistoffen

Ongoing
2
20
Europe
Tysabri (natalizumab), Concentrate and solvent for solution for infusion, Tysabri
Erasmus University Medical Center, Biogen Idec International B.V.
Anti-Hu associated paraneoplastic neurological syndromes, Anti-Hu associated paraneoplastic neurological syndromes, Diseases [C] - Immune System Diseases [C20]
 
 
2019-003127-38: Research on the effect of add-on high dosage simvastatin treatment on progression in MS patients treated with ocrelizumab and natalizumab. Onderzoek naar het effect van het toevoegen van hoge dosis simvastatine op progressie van MS patiënten die behandeld worden met ocrelizumab en natalizumab.

Not yet recruiting
2
100
Europe
Simvastatin, Tablet
VUmc Neurology Department, Stichting MS Research
Multiple sclerosis Multiple sclerose, Multiple sclerosis Multiple sclerose, Diseases [C] - Nervous System Diseases [C10]
 
 
2022-002654-95: No Evidence Of Disease Activity After Autologous Haematopoietic Stem Cell Transplantation In Aggressive Multiple Sclerosis Nessuna evidenza di attività della malattia dopo trapianto autologo di cellule staminali ematopoietiche nella Sclerosi Multipla aggressiva

Not yet recruiting
2
90
Europe
OCREVUS, Kesimpta 20 mg soluzione iniettabile, TYSABRI, LEMTRADA, Non disponibile, Solution for injection, Powder for concentrate for solution for infusion, Powder and solvent for concentrate for solution for infusion, Concentrate for solution for infusion, Powder and solvent for solution for injection, Powder for solution for injection, OCREVUS, Kesimpta, TYSABRI, LEMTRADA
FONDAZIONE ITALIANA SCLEROSI MULTIPLA ONLUS, Fondazione Italiana Sclerosi Multipla
Relapsing Remitting Multiple Sclerosis Sclerosi multipla recidivante remittente, A type of MS where you have relapses (symptoms getting worse) followed by recovery (that's when it's “remitting”) Forma di Sclerosi Multipla nella quale in cui si hanno ricadute (sintomi che peggiorano) seguite da guarigione (le remissioni)., Diseases [C] - Nervous System Diseases [C10]
 
 
NCT05418010: Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS)

Suspended
2
40
Europe
Tysabri Injectable Product, Natalizumab, Placebo
Queen Mary University of London, Biogen, UCL Queen Square Institute of Neurology, Moorfields Eye Hospital NHS Foundation Trust, Barts & The London NHS Trust
Multiple Sclerosis, Clinically Isolated Syndrome of Demyelination
01/28
01/28
2008-005871-92: En fas 1 studie av effekt av Tysabri (natalizumab), en IgG4 humaniserad monoklonal antikropp specifik mot VLA-4 (integrin alfa-4), administrerad som infusion 1 gång/månad under 3 månader hos patienter med kronisk idiopatisk trombocytopen purpura (ITP).

Ongoing
1/2
20
Europe
Tysabri, Tysabri, Tysabri
Sahlgrenska University Hospital
Chronic idiopathic thrombocytopenic purpura (ITP)
 
 
NCT03811886: Natalizumab in Recurrent, Refractory or Progressive Pulmonary Metastatic Osteosarcoma

Withdrawn
1/2
20
US
Natalizumab, Tysabri
Case Comprehensive Cancer Center
Pulmonary Metastatic Osteosarcoma (pOS)
12/25
10/26
NCT03093064: Inflammatory Response In Schizophrenia

Completed
1
66
Europe
Natalizumab, Tysabri, Placebo: normal saline
King's College London, South London and Maudsley NHS Foundation Trust
Schizophrenia
06/23
08/23
NCT05618301: Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD)

Active, not recruiting
1
10
US
Motixafortide, BL-8040, Natalizumab, Tysabri, Leukapheresis
Washington University School of Medicine, BioLineRx, Ltd., Biogen
Sickle Cell Disease
06/25
06/25
NCT06705608: Examining the Risk of Skin Cancer in Multiple Sclerosis Patients Using Fingolimod: a Population-Based Study

Completed
N/A
4000
NA
Fingolimod, Natalizumab, Dimethyl fumarate (DMF), Alemtuzumab, Teriflunomide
University of British Columbia
Multiple Sclerosis, Skin Cancer, Skin Cancer Melanoma, Skin Cancers - Basal Cell Carcinoma, Skin Cancer, Squamous Cell, Multiple Sclerosis (MS) - Relapsing-remitting
12/20
12/20
CPE, NCT05762003: Czech Pharmaco-epidemiological Study on Disease Modifying Drugs

Completed
N/A
17478
RoW
interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab
IMPULS Endowment Fund
Multiple Sclerosis
12/21
12/21
NCT04964700: Analysis of MS Patients Who Have Had Greater Than 60 Infusions of Natalizumab

Active, not recruiting
N/A
42
US
Natalizumab, Tysabri
Multiple Sclerosis Center of Northeastern New York
Multiple Sclerosis
04/22
06/22
COMBAT-MS, NCT03193866 / 2016-003587-39: COMparison Between All immunoTherapies for Multiple Sclerosis.

Completed
N/A
3526
Europe
Rituximab, Natalizumab, Fingolimod, Alemtuzumab, Interferon-beta, Glatiramer acetate, Dimethyl Fumarate
Karolinska Institutet, Patient-Centered Outcomes Research Institute, Kaiser Foundation Research Institute
Relapsing-remitting Multiple Sclerosis
03/22
03/22
NCT05627271: The 'Wearing Off' Effect of DMT

Completed
N/A
39
Europe
ocrelizumab, Ocrevus, natalizumab, Tysabri, ofatumumab, Kesimpta
Novartis Pharmaceuticals
Multiple Sclerosis
04/23
04/23
TYPIFI, NCT04832399: Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants

Completed
N/A
60
Europe
Natalizumab, Tysabri, BG00002
Biogen
Relapsing Remitting Multiple Sclerosis
10/23
10/23
NCT04565431: Examining Effects of Tysabri on Cognitive Fatigue Using fMRI

Recruiting
N/A
25
US
Tysabri
Kessler Foundation, St. Barnabas Medical Center
Multiple Sclerosis, Relapsing-Remitting
12/24
12/24
NCT05304520: A Study for Tysabri Participant Preference

Completed
N/A
318
Europe
Natalizumab
Biogen
Relapsing-Remitting Multiple Sclerosis (RRMS)
04/24
04/24
BABYZUMAB-2, NCT05209815: Safety of Exposure to Natalizumab During Pregnancy

Completed
N/A
68
Europe, RoW
Questionnaire
University Hospital, Bordeaux, Biogen
Multiple Sclerosis
12/23
12/23
NCT03399981: Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries

Completed
N/A
80327
US
Tysabri, Natalizumab BG00002
Biogen
Progressive Multifocal Leukoencephalopathy
12/23
12/23
Tys at Home, NCT04777539: Comparing the Safety and Benefit of Natalizumab (Tysabri®) At-home Infusion vs At-hospital Infusion in Multiple Sclerosis

Active, not recruiting
N/A
279
Europe
At-home natalizumab treated MS patient
Nantes University Hospital, Rennes University Hospital
Multiple Sclerosis (MS)
11/24
05/25
SATURATE-MS, NCT05701423: A Study of End of Dose Phenomena in Subcutaneous Natalizumab Treated Multiple Sclerosis (MS) Participants

Terminated
N/A
34
Europe
Natalizumab, Tysabri
Biogen
Multiple Sclerosis
07/24
07/24
NCT05925049: A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)

Active, not recruiting
N/A
400
US
Natalizumab, Tysabri
Biogen
Multiple Sclerosis
12/25
12/25
NCT05236777: TOPIK Study: A Study to Report Progressive Multifocal Leukoencephalopathy and Other Serious Opportunistic Infections in Natalizumab Treated Participants

Completed
N/A
675
RoW
Natalizumab, Tysabri
Biogen, ReMuS Registry
Multiple Sclerosis
04/25
04/25
TREAT-MS, NCT03500328: Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial

Active, not recruiting
N/A
900
US
Natalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq, Tysabri, Lemtrada, Ocrevus, Rituxan/Riabni/Truxima/Ruxience, Mavenclad, Kesimpta, Briumvi, Ocrevus Zunovo, Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod, Copaxone, Glatopa, Avonex, Betaseron, Extavia, Rebif, Plegridy, Aubagio, Tecfidera, Vumerity, Bafiertam, Gilenya, Mayzent, Zeposia, Ponvory, Tascenso
Johns Hopkins University, Patient-Centered Outcomes Research Institute, National Multiple Sclerosis Society
Multiple Sclerosis, Relapsing-Remitting
08/26
08/26
NCT00493298: Tysabri Observational Program

Checkmark TOP
Jun 2014 - Jun 2014: TOP
Checkmark ACTRIMS 2014: MS (TOP)
Jun 2014 - Jun 2014: ACTRIMS 2014: MS (TOP)
Checkmark EFNS-ENS 2014: MS (TOP)
More
Completed
N/A
6620
Europe, Canada, RoW
Tysabri, BG00002, natalizumab
Biogen
Relapsing-Remitting Multiple Sclerosis
11/23
11/23
NCT05688436: A Study to Assess Pregnancy Outcomes in Women Exposed to Diroximel Fumarate

Recruiting
N/A
1178
US
Diroximel Fumarate, VUMERITY, BIIB098, Alemtuzumab, Fingolimod, Glatiramer acetate, Interferon beta, Natalizumab, Tysabri, BG00002, Ocrelizumab, Ofatumumab, Ozanimod, Peginterferon beta-1a, Ponesimod, Siponimod
Biogen
Multiple Sclerosis
01/31
01/31
NCT05658497: Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)

Recruiting
N/A
908
Europe, US
Diroximel Fumarate, VUMERITY, BIIB098, Avonex, BG9418, interferon beta-1a, Tysabri, Natalizumab, BG00002, Dimethyl Fumarate, Tecfidera, DMF, BG00012
Biogen
Multiple Sclerosis
07/32
07/32
Qinprezo (vosaroxin) / Denovo
BIG-1, NCT02416388: Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR

Recruiting
2/3
3100
Europe
Idarubicin, Daunorubicin, HD Cytarabine, Cyclosporine, Methotrexate, Mycophenolic acid (MPA), vosaroxin, ID cytarabine, Dexamethasone, Venetoclax
University Hospital, Angers
Acute Myeloid Leukemia (AML)
07/25
01/32
VITAL, NCT02658487: Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia

Completed
2
42
US
Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosar-U, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Vosaroxin, AG-7352, SNS-595, SPC 595, Voreloxin
Vanderbilt-Ingram Cancer Center, National Cancer Institute (NCI)
Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia With Multilineage Dysplasia, Myeloid Sarcoma, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia, Therapy-Related Myelodysplastic Syndrome
04/19
09/24
2015-004066-28: A Phase II Study with a Safety Run-in Phase Evaluating Vosaroxin With Azacitidine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia and Intermediate/Adverse Genetic Risk or Myelodysplastic Syndrome with Excess Blasts-2 (MDS-EB-2) - AMLSG 24-15 Studie mit einem Dosisfindungsteil gefolgt von einem Phase II-Teil zu Vosaroxin in Kombination mit Azacitidin bei Patienten mit akuter myeloischer Leukämie und intermediärem bzw. ungünstigem genetischem Risiko oder myelodysplastischen Syndrom mit Exzess von Blasten (MDS-EB-2) (AMLSG 24-15)

Not yet recruiting
2
168
Europe
Azacitidine, Vosaroxin, not applicalbe, Powder for injection, Injection, Vidaza
University Hospital Ulm, SUNESIS PHARMACEUTICALS, INC, University Hospital Ulm
Patients with confirmed diagnosis of acute myeloid leukemia (WHO 2016) and intermediate or adverse genetic risk (according to 2017 ELN recommendations); or patients with myelodysplastic syndrome with excess blasts-2 (MDS-EB-2) Patienten mit bestätigter Diagnose einer akuten myeloischen Leukämie (WHO 2016) und intermediärem oder ungünstigem genetischem Risiko (entsprechend den ELN Empfehlungen 2017); oder Patienten mit myelodysplastischem Syndrom mit Exzess von Blasten (MDS-EB-2), Patients with Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with Excess Blasts-2 (MDS-EB-2) Patienten mit Neu diagnostizierte akute myeloische Leukämie oder myelodysplastisches Syndrom mit Exzess von Blasten (MDS-EB-2), Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT01913951: Vosaroxin and Azacitidine in Treating Patients With Myelodysplastic Syndromes

Checkmark For vosaroxin and azacitidine combination trial in myelodysplastic syndrome at EHA 2017
Jun 2017 - Jun 2017: For vosaroxin and azacitidine combination trial in myelodysplastic syndrome at EHA 2017
Checkmark ASH 2015
Dec 2015 - Dec 2015: ASH 2015
Completed
1
35
US
vosaroxin, voreloxin, Azacitidine, Vidaza, Ladakamycin
Washington University School of Medicine, Sunesis Pharmaceuticals
Myelodysplastic Syndromes
12/16
04/24
ampreloxetine (TD-9855) / Theravance Biopharma
CYPRESS, NCT05696717: Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy

Recruiting
3
102
Europe, Canada, US, RoW
Ampreloxetine, TD-9855, Placebo
Theravance Biopharma
Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy
12/24
01/27
Spinraza (nusinersen) / Biogen
2020-005180-30: Etude des effets fonctionnels du nusinersen chez des personnes amyotrophiques spinaux adultes par déficit génétique 5q de type 2 ou 3 : étude expérimentale en cas unique en lignes de base multiples à travers les sujets, multicentrique, randomisée, en simple aveugle Etude des effets fonctionnels du nusinersen chez des personnes amyotrophiques spinaux adultes par déficit génétique 5q de type 2 ou 3 : étude expérimentale en cas unique en lignes de base multiples à travers les sujets, multicentrique, randomisée, en simple aveugle

Not yet recruiting
4
24
Europe
Solution for injection, Spinraza
Centre Hospitalier Universitaire de Reims, Centre Hospitalier Universitaire de Reims
tout patient éligible (patient 5q SMA type 2 ou 3 pour lequel le traitement par nusinersen a été validé par le centre de référence et de compétence des maladies neuromusculaires et un neurologue). Une information concernant les objectifs et les modalités de la recherche lui sera donnée à l’aide de la note d’information. Si le patient accepte de participer à la recherche, il devra signer le consentement de participation. tout patient éligible (patient 5q SMA type 2 ou 3 pour lequel le traitement par nusinersen a été validé par le centre de référence et de compétence des maladies neuromusculaires et un neurologue). Une information concernant les objectifs et les modalités de la recherche lui sera donnée à l’aide de la note d’information. Si le patient accepte de participer à la recherche, il devra signer le consentement de participation., tout patient éligible (patient 5q SMA type 2 ou 3 pour lequel le traitement par nusinersen a été validé par le centre de référence et de compétence des maladies neuromusculaires et un neurologue) tout patient éligible (patient 5q SMA type 2 ou 3 pour lequel le traitement par nusinersen a été validé par le centre de référence et de compétence des maladies neuromusculaires et un neurologue), Diseases [C] - Musculoskeletal Diseases [C05]
 
 
2019-005007-40: Natural history study in adult patients with SMA types 2-3-4 and Role of neurodegenerative and neuro-inflammatory biomarkers in SMA adults treated with nusinersen. Studie van het natuurlijk ziekteverloop bij volwassen patiënten met spinale spieratrofie (SMA) en de rol van biomerkers bij SMA patiënten die met nusinersen behandeld worden.

Not yet recruiting
4
19
Europe
Solution for injection, Spinraza
University Hospitals Leuven, Biogen
Adult patients with spinal muscular atrophy (SMA) type 2, type 3, or type 4, spinal muscular atrophy (SMA), Diseases [C] - Nervous System Diseases [C10]
 
 
RESPOND, NCT04488133 / 2020-003492-18: A Study to Learn About the Effect of Nusinersen (BIIB058) Given as Injections to Children With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec

Active, not recruiting
4
46
Europe, US, RoW
Nusinersen, ISIS 396443, BIIB058, Spinraza
Biogen
Muscular Atrophy, Spinal
10/25
10/25
RISE, NCT05522361: Risdiplam in Patients With Spinal Muscular Atrophy Previously Treated With Nusinersen

Active, not recruiting
4
10
US
Risdiplam
Clinic for Special Children, Genentech, Inc.
Spinal Muscular Atrophy
12/25
06/26
2021-006709-31: Phase IIIb, open-label, multi-center study to evaluate safety, tolerability and efficacy study of OAV101 administered intrathecally to participants with spinal muscular atrophy (SMA) who have discontinued treatment with nusinersen or risdiplam

Ongoing
3
28
Europe
OAV101, OAV101, Solution for injection, Zolgensma
Novartis Pharma AG, Novartis Pharma AG
Spinal Muscular Atrophy, Spinal Muscular Atrophy, Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
 
 
SHINE, NCT02594124 / 2015-001870-16: A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies

Completed
3
292
Europe, Canada, Japan, US, RoW
nusinersen, ISIS 396443, Spinraza, BIIB058, IONIS SMN Rx, ISIS SMNRx
Biogen
Spinal Muscular Atrophy
08/23
08/23
DEVOTE, NCT04089566 / 2019-002663-10: Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy

Completed
3
145
Europe, Canada, Japan, US, RoW
Nusinersen, BIIB058
Biogen
Muscular Atrophy, Spinal
02/24
05/24
SAPPHIRE, NCT05156320 / 2021-005314-34: Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam

Completed
3
188
Europe, US
Apitegromab, SRK-015, Placebo
Scholar Rock, Inc.
Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3, Spinal Muscular Atrophy Type 2, SMA, Neuromuscular Diseases, Muscular Atrophy, Atrophy, Muscular Atrophy, Spinal, Neuromuscular Manifestations, Anti-myostatin
12/24
12/24
STRENGTH, NCT05386680: Phase IIIb, Open-label, Multi-center Study to Evaluate Safety, Tolerability and Efficacy of OAV101 Administered Intrathecally to Participants With SMA Who Discontinued Treatment With Nusinersen or Risdiplam

Completed
3
27
Europe, Canada, Japan, US, RoW
OAV101, AVXS-101, Zolgensma
Novartis Pharmaceuticals
Spinal Muscular Atrophy
11/24
11/24
ONWARD, NCT04729907 / 2020-004708-32: A Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Took Part in an Earlier Nusinersen Trial

Active, not recruiting
3
115
Europe, Canada, Japan, US, RoW
Nusinersen, BIIB058, Spinraza
Biogen, Biogen Idec Research Limited
Muscular Atrophy, Spinal
07/26
07/26
ASCEND, NCT05067790 / 2021-001294-23: A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam

Active, not recruiting
3
45
Europe, Japan, US, RoW
Nusinersen, BIIB058, Spinraza
Biogen
Spinal Muscular Atrophy
06/27
06/27
NURTURE, NCT02386553 / 2014-002098-12: A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy

Completed
2
25
Europe, Canada, US, RoW
Nusinersen, ISIS 396443, BIIB058, ISIS SMNRx, Spinraza
Biogen
Spinal Muscular Atrophy
12/24
12/24
OPAL, NCT07047144: A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy

Not yet recruiting
2
52
NA
Apitegromab, SRK-015, Nusinersen, Spinraza, Risdiplam, Evrysdi
Scholar Rock, Inc.
Spinal Muscular Atrophy, SMA, Spinal Muscular Atrophy Type 2, Spinal Muscular Atrophy Type 3, Neuromuscular Manifestations, Anti-myostatin
11/28
03/29
ChiCTR2200063672: EC50 of propofol with target controlled infusion for intrathecal injection of Nusinersen in children with spinal muscular atrophy

Not yet recruiting
1
30
 
Target controlled infusion of propofol for intravenous anesthesia
The First Affiliated Hospital of Fujian Medical University; The First Affiliated Hospital of Fujian Medical University, self-raised
Spinal muscular atrophy
 
 
PIERRE-PK, NCT06555419: A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy

Recruiting
1
58
Europe, US
Nusinersen, BIIB058, ThecaFlex DRx System
Biogen, Alcyone Therapeutics, Inc
Muscular Atrophy, Spinal
05/26
05/26
NCT02865109: Expanded Access Program (EAP) for Nusinersen in Participants With Infantile-onset (Consistent With Type 1) Spinal Muscular Atrophy (SMA)

No Longer Available
N/A
RoW
Nusinersen, ISIS 396443, BIIB058, Spinraza
Biogen
Infantile-onset Spinal Muscular Atrophy
 
 
NCT03878030: Effect of Nusinersen on Adults With Spinal Muscular Atrophy

Completed
N/A
12
US
nusinersen, Spinraza
Northwell Health
Adult Spinal Muscular Atrophy
07/21
07/21
NCT04674618: Ultrasound-assisted vs Landmark Based Intrathecal Administration of Nusinersen

Completed
N/A
58
Europe
US-assisted nusinersen administration
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Muscular Atrophy, Spinal, Ultrasound
12/21
12/23
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Skytrofa (lonapegsomatropin-tcgd) / Ascendis
2021-004313-39: An extension study to check the safety of once weekly lonapegsomatropin when given for a long time in adults with growth hormone deficiency. Μία μελέτη επέκτασης για τον έλεγχο της ασφάλειας της άπαξ εβδομαδιαίως δόσης Lonapegsomatropin όταν χορηγείται για μεγάλο χρονικό διάστημα σε ενήλικες με ανεπάρκεια αυξητικής ορμόνης

Not yet recruiting
3
240
Europe
lonapegsomatropin drug product, ACP-011, Powder and solvent for solution for injection
Ascendis Pharma Endocrinology Division A/S, Ascendis Pharma Endocrinology Division A/S
Adult Growth Hormone Deficiency (AGHD) Ανεπάρκεια Αυξητικής Ορμόνης Ενηλίκων (AGHD), Lack of growth hormone in the body Έλλειψη αυξητικής ορμόνης στο σώμα, Diseases [C] - Hormonal diseases [C19]
 
 
enliGHten, NCT03344458 / 2017-003410-20: A Long-Term Trial Investigating Safety and Efficacy of TransCon hGH in Children With Growth Hormone Deficiency Who Have Completed a Prior TransCon hGH Clinical Trial

Completed
3
298
Europe, US, RoW
TransCon hGH
Ascendis Pharma A/S
Growth Hormone Deficiency, Pediatric, Endocrine System Diseases, Hormone Deficiency, Pituitary Diseases
02/23
02/23
foresiGHt, NCT04615273 / 2020-000929-42: A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency

Completed
3
264
Europe, Canada, Japan, US, RoW
Lonapegsomatropin, Placebo, Somatropin
Ascendis Pharma Endocrinology Division A/S
Growth Hormone Deficiency, Endocrine System Diseases, Hormone Deficiency
11/23
12/23
NCT05171855 / 2021-004313-39: A Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency

Completed
3
233
Europe, Canada, Japan, US, RoW
Lonapegsomatropin, ACP-011
Ascendis Pharma Endocrinology Division A/S, Ascendis Pharma Endocrinology Division A/S
Adult Growth Hormone Deficiency, Endocrine System Diseases, Hormone Deficiency
12/24
12/24
COACH, NCT06433557: A Phase 2 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of Navepegritide in Combination With Lonapegsomatropin in Children With Achondroplasia

Active, not recruiting
2
22
Europe
Combination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injections
Ascendis Pharma Growth Disorders A/S
Achondroplasia
09/25
09/27
NCT05690386: A Trial to Investigate Different Doses of Lonapegsomatropin Compared to Somatropin in Individuals With Turner Syndrome

Active, not recruiting
2
48
US
Lonapegsomatropin, Somatropin
Ascendis Pharma Endocrinology Division A/S
Turner Syndrome
12/24
12/27
SkyPASS, NCT05775523: A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin

Recruiting
N/A
500
US
No intervention
Ascendis Pharma Endocrinology Division A/S
Growth Hormone Deficiency
03/33
03/33
SkybriGHt, NCT05820672: A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA

Recruiting
N/A
900
US
No intervention
Ascendis Pharma Endocrinology Division A/S
Growth Hormone Deficiency
03/33
03/33
pelacarsen (AKCEA-APO(a)-LRx) / Novartis
2021-003059-41: A multicenter trial assessing the impact of lipoprotein(a) lowering with pelacarsen (TQJ230) on the rate of weekly lipoprotein apheresis sessions in patients with hyperlipoproteinemia(a) and established cardiovascular disease in Germany.

Not yet recruiting
3
46
Europe
Pelacarsen, TQJ230, Solution for injection in pre-filled syringe
Novartis Pharma AG, Novartis Pharma AG
Cardiovascular Disease, Apheresis, Diseases [C] - Cardiovascular Diseases [C14]
 
 
NCT06267560: Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD

Recruiting
3
400
US
TQJ230, pelacarsen, Placebo
Novartis Pharmaceuticals
Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease
03/27
03/27
NCT05305664: A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Rate of Weekly Lipoprotein Apheresis Sessions in Patients With Hyperlipoproteinemia(a) and Established Cardiovascular Disease in Germany

Completed
3
51
Europe
Pelacarsen (TQJ230) 80 mg s.c., TQJ230, Corresponding Placebo, Placebo
Novartis Pharmaceuticals
Hyperlipoproteinemia(a)
01/25
01/25
ADD-VANTAGE, NCT06813911: Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD

Recruiting
3
340
US
Pelacarsen, TQJ230, Placebo, Inclisiran
Novartis Pharmaceuticals
Atherosclerotic Cardiovascular Disease (ASCVD)
11/27
12/27
NCT06875973: Pelacarsen Roll-over Extension Program

Not yet recruiting
3
600
NA
Pelacarsen (TQJ230), TQJ230
Novartis Pharmaceuticals
Atherosclerotic Cardiovascular Disease
12/27
01/28
Lp(a)HORIZON, NCT04023552 / 2019-001076-11: Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD

Active, not recruiting
3
8323
Europe, Canada, Japan, US, RoW
TQJ230, Placebo, Placebo to match TQJ230
Novartis Pharmaceuticals
Cardiovascular Disease and Lipoprotein(a)
02/26
02/26
OLE, NCT05900141: An Open Label Extension () Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

Active, not recruiting
3
41
Europe
Pelacarsen, TQJ230
Novartis Pharmaceuticals
Hyperlipoproteinemia (a)
08/28
08/28
NCT05646381: A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis

Recruiting
2
502
Europe, Canada, US, RoW
Pelacarsen (TQJ230) 80mg, TQJ230, Matching placebo, Placebo
Novartis Pharmaceuticals
Aortic Stenosis
03/30
03/30
NCT07000695: Managed Access Programs for TQJ230, Pelacarsen

Available
N/A
NA
Pelacarsen, TQJ230
Novartis Pharmaceuticals
Atherosclerotic Cardiovascular Disease, ASCVD
 
 
TQJ230, NCT05548023: Time-trend Analysis of Clinical Characteristic and Outcomes in Patients With Unprotected Left Main Coronary Artery Disease Treated With PCI Over a 10-year Period

Active, not recruiting
N/A
500
RoW
The AngioliteTM Durable Fluoroacrylate Polymer-based Sirolimus-Eluting Stent
Chinese University of Hong Kong
Cardiovascular Diseases
12/24
02/25
Adlyxin (lixisenatide) / Sanofi
2014-002178-35: The renal effects of lixisenatide (a novel, gut-hormone based diabetes drug) and insulin glulisine (a common, wideley diabetes drug) Een onderzoek naar de werking van lixisenatide (een nieuw, op darmhormoon gebaseerd diabetes medicijn) en insuline glulisine (een veelgebruikt gangbaar diabetes medicijn) op de nierfunctie

Ongoing
4
40
Europe
Lixisenatide, Insulin glulisine, Lyxumia, Apidra, Lyxumia, Apidra
VU University Medical Center, VU University Medical Center, Sanofi-Aventis Netherlands B.V.
Type 2 Diabetes Mellitus Type 2 Diabetes
 
 
2016-001758-17: Lixisenatide Arterial Stiffness Trial

Ongoing
4
120
Europe
Lixisenatide (Lyxumia), Suspension for injection in pre-filled pen, Lyxumia
King's College London, Guy's and St Thomas' NHS Foundation Trust, Sanofi Aventis Limited
Type 2 diabetes, Diabetes, Diseases [C] - Hormonal diseases [C19]
 
 
ChiCTR2000037907: Effects of DPP-4 inhibitors on health-related quality of life in patients with type 2 diabetes

Not yet recruiting
4
600
 
DPP-4 inhibitors (including sitagliptin, sitagliptin, vildagliptin, linagliptin, alogliptin) ;GLP-1 receptor agonists (including exenatide, liraglutide, benaglutide, lixisenatide) ;SGLT-2 inhibitor (including dapagliflozin, empagliflozin, canagliflozin)
Shanghai Minhang Hospital; Shanghai Minhang Hospital, 2019 Shanghai Health Commission Research Project
Type 2 diabetes
 
 
NCT05804513: The Effect of Lixisenatide on the Effect of Pituitary Hormones

Recruiting
4
10
Europe
Placebo, Sodium chloride 0.9% solution, Lixisenatide 10 micrograms (50 micrograms/ml in 3 ml) Pen Injector, Lyxumia
University of Tartu, Tartu University Hospital
Healthy, Type 1 Diabetes
10/23
12/23
NCT06449235: Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh

Not yet recruiting
4
938
RoW
Omarigliptin, Sulphonylureas, Metformin, Other DPP4-i, Thiazolidinediones, Alpha-Glucosidase Inhibitor, Glucagon-Like Peptide-1, Receptor Agonists (GLP1RA), SGLT2 inhibitors
Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders, Pi Research and Development Center, Acme Laboratories Ltd.
Type2diabetes
04/25
06/25
2013-002259-14: The LIXI trial is aiming to recruit individuals with type 1 diabetes who are using insulin to control their disease. The trial is investigating whether a daily injection of a newly-licenced drug called lixisenatide, taken alongside a person\'s usual insulin medication can improve blood sugar levels after meals.

Ongoing
2
33
Europe
Lixisenatide 10 micrograms, Lixisenatide 20 micrograms, N/A, Lyxumia, Lyxumia
University of Oxford, Aventis Pharma Limited (Sanofi)
Type 1 diabetes mellitus
 
 
NCT02244164: Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.

Terminated
N/A
5
Europe
Incretinomimetics, - exenatide (Byetta®), - liraglutide (Victoza®), - lixisenatide (Lyxumia®), - exenatide extended-release (Bydureon®)., DPP-4 inhibitors, - sitagliptine (Januvia®), - vildagliptine (Galvus®), - saxagliptine (Onglyza®), - linagliptine (Trajenta®).
Erasme University Hospital
Type 2 Diabetes, Incretinomimetics, Pancreas
02/23
02/23
SEVERAL, NCT05136287: SEMAGLUTIDE VERSUS GLP-1 RECEPTOR AGONISTS. EFFECTIVENESS , SAFETY AND QUALITY OF LIFE IN PATIENTS WITH DIABETES MELLITUS 2. OBSERVATIONAL, PROSPECTIVE AND MULTICENTER STUDY. STUDY.

Completed
N/A
140
Europe
GLP-1 receptor agonist
Jose Seijas Amigo
Weight Loss, Diabetes Mellitus, Type 2, Quality of Life, Safety Issues
11/23
01/24
CER-4-T2D, NCT05220917: Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study

Active, not recruiting
N/A
781430
US
SGLT2 inhibitor, CANAGLIFLOZIN, CANAGLIFLOZIN/METFORMIN HCL, DAPAGLIFLOZIN PROPANEDIOL/METFORMIN HCL, DAPAGLIFLOZIN PROPANEDIOL, EMPAGLIFLOZIN, EMPAGLIFLOZIN/METFORMIN HCL, ERTUGLIFLOZIN PIDOLATE/METFORMIN HCL, ERTUGLIFLOZIN PIDOLATE, EMPAGLIFLOZIN/LINAGLIPTIN, EMPAGLIFLOZIN/LINAGLIPTIN/METFORMIN HCL, DAPAGLIFLOZIN PROPANEDIOL/SAXAGLIPTIN HCL, ERTUGLIFLOZIN PIDOLATE/SITAGLIPTIN PHOSPHATE, DPP-4 inhibitor, ALOGLIPTIN BENZOATE/METFORMIN HCL, ALOGLIPTIN BENZOATE, ALOGLIPTIN BENZOATE/PIOGLITAZONE HCL, SAXAGLIPTIN HCL, SAXAGLIPTIN HCL/METFORMIN HCL, LINAGLIPTIN, LINAGLIPTIN/METFORMIN HCL, SITAGLIPTIN PHOSPHATE/METFORMIN HCL, SITAGLIPTIN PHOSPHATE, SITAGLIPTIN PHOSPHATE/SIMVASTATIN, GLP-1RA, INSULIN DEGLUDEC/LIRAGLUTIDE*, INSULIN GLARGINE, HUMAN RECOMBINANT ANALOG/LIXISENATIDE*, LIXISENATIDE, LIRAGLUTIDE, DULAGLUTIDE, SEMAGLUTIDE, ALBIGLUTIDE, EXENATIDE MICROSPHERES, EXENATIDE, 2nd generation SU, PIOGLITAZONE HCL/GLIMEPIRIDE, ROSIGLITAZONE MALEATE/GLIMEPIRIDE, GLIPIZIDE/METFORMIN HCL, GLYBURIDE,MICRONIZED, GLYBURIDE/METFORMIN HCL, GLIMEPIRIDE, GLYBURIDE, GLIPIZIDE
Brigham and Women's Hospital, Patient-Centered Outcomes Research Institute, VA Boston Healthcare System, McGill University
Cardiovascular Events, Type2 Diabetes, Renal Disease
07/24
07/24
omecamtiv mecarbil (AMG 423) / Amgen, Servier
2020-003057-30: Omecamtiv Mecarbil Post-trial Access Protocol for Subjects Completing Study 20110203 GALACTIC-HF

Not yet recruiting
3
1286
Europe
Omecamtiv mecarbil, AMG 423, Modified-release tablet
Amgen Inc., Amgen Inc.
Chronic heart failure with reduced ejection fraction, Chronic Heart Failure, Diseases [C] - Cardiovascular Diseases [C14]
 
 
COMET-HF, NCT06736574: Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

Recruiting
3
1800
US
Omecamtiv Mecarbil (OM), Placebo
Cytokinetics
Heart Failure, Heart Failure With Reduced Ejection Fraction
09/27
12/27
Tysabri (natalizumab) / Biogen, Royalty
2007-007394-22: The role of white and grey matter and meningeal inflammation in multiple sclerosis (MS) and clinically isolated syndromes (CIS) as quantified using [(11)C](R)-PK11195 positron emission tomography (PET) scanning

Ongoing
4
10
Europe
Tysabri, Tysabri, Tysabri
Imperial College London
Multiple Sclerosis
 
 
2013-004626-28: Aivojen mikroglia-solujen aktivaation yhteys MS-tautiin

Ongoing
4
60
Europe
beetainterferoni -1a, Fingolimodi, REBIF, Gilenya, Avonex, Betaferon, Copaxone, Tysabri, Lemtrada, REBIF, Gilenya, Avonex, Betaferon, Copaxone, Tysabri, Lemtrada
Turku University Hospital, Novartis Pharma
Multiple sclerosis MS-tauti
 
 
2016-000345-31: Reduce the number of natalizumab infusions in patients with multiple sclerosis Verminderen van het aantal giften van natalizumab bij patiënten met multiple sclerose

Ongoing
4
60
Europe
natalizumab, Solution for infusion, tysabri
VU medical center, de Hersenstichting
multiple sclerosis multiple sclerose, MS MS, Diseases [C] - Nervous System Diseases [C10]
 
 
2017-002634-24: MultipleMS – a study with the aim to accelerate personalised medicine in multiple sclerosis. MultipleMS - en studie med syftet att utveckla precisionsmedicin för multipel skleros.

Ongoing
4
150
Europe
Infusion, Capsule, Tablet, Injection, Mabthera, Tysabri, Tecfidera, Gilenya, Copaxone, Betaferon, Extavia, Avonex, Rebif, Plegridy, Lemtrada, Aubagio
Karolinska Institutet, Department of Clinical Neuroscience, Karolinska Institutet
Newly diagnosed patients with Clinically Isolated Syndrome (CIS) and multiple sclerosis (MS) -both relapsing remitting and primary progressive), Multiple sclerosis (MS) is an autoimmune disorder of the central nervous system (CNS), characterized by repeated episodes of inflammation in the CNS leading to various neurological symptoms., Diseases [C] - Nervous System Diseases [C10]
 
 
2013-002433-38: Essai visant à tester la différence d’efficacité du Natalizumab, versus le fingolimod, 2 médicaments pour le traitement de la sclérose en plaques

Not yet recruiting
4
500
Europe
natalizumab, fingolimod, Concentrate for solution for infusion, Capsule, TYSABRI, GILENYA
CHU de Toulouse, FP7 Health Innovation-1
Sclérose en plaques, Sclérose en plaques, Diseases [C] - Nervous System Diseases [C10]
 
 
2019-002566-13: Personalizing the treatment with natalizumab in patients with multiple sclerosis

Not yet recruiting
4
300
Europe
natalizumab, Solution for infusion, Tysabri
Amsterdam University Medical Center, Innovatiefonds Zorgverzekeraars, Stichting MS Research, de Hersenstichting
Relapsing remitting multiple sclerosis, Multiple sclerosis (MS), Diseases [C] - Nervous System Diseases [C10]
 
 
NCT04048577: A Pilot Study to Characterize the Biological Effect of a Pre-planned 12 Week Dose Interruption of Natalizumab

Recruiting
4
10
US
Dosing Interruption of Natalizumab, Dosing Interruption of Tysabri
Berkovich, Regina MD, PhD Inc., Biogen, Cedars-Sinai Medical Center
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
11/21
12/21
NAPPREMS, NCT03046251: Natalizumab in Preventing Post-partum Relapses in Multiple Sclerosis

Completed
4
30
US
Natalizumab
State University of New York at Buffalo
Multiple Sclerosis
12/23
12/23
NCT05532163: A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)

Terminated
4
1
Europe
Natalizumab, Tysabri, BG00002
Biogen
Multiple Sclerosis, Relapsing-Remitting
10/23
10/23
NTZ2TTY, NCT02769689: Methylprednisolone During the Switch Between Natalizumab and Fingolimod

Recruiting
4
56
Europe
Methylprednisolone, Placebo, natalizumab (NTZ), fingolimob (FTY)
University Hospital, Clermont-Ferrand
Multiple Sclerosis
06/24
07/24
NCT04178005: Cladribine Tablets After Treatment With Natalizumab (CLADRINA)

Active, not recruiting
4
40
US
Cladribine, Mavenclad
University of Texas Southwestern Medical Center, EMD Serono
Multiple Sclerosis
08/26
12/26
NCT05177718: Natalizumab and Chronic Inflammation

Terminated
4
1
US
Natalizumab 300 MG in 15 ML Injection
Vanderbilt University Medical Center, Biogen
Multiple Sclerosis
04/23
04/23
SUPERNEXT, NCT04225312: Personalized Extended Interval Dosing of Natalizumab in Relapsing Remitting Multiple Sclerosis

Enrolling by invitation
4
300
Europe
Personalized extended interval dosing of natalizumab, EID, Standard interval dosing, SID
Amsterdam UMC, location VUmc, Stichting MS Research, Innovatiefonds Zorgverzekeraars, Stichting Treatmeds
Relapsing Remitting Multiple Sclerosis
03/25
03/25
DELIVER-MS, NCT03535298: Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS

Active, not recruiting
4
800
Europe, US
Early Highly Effective Therapies Group, Lemtrada (alemtuzumab), Ocrevus (ocrelizumab), Tysabri (natalizumab), Rituxan (rituximab), Kesimpta (ofatumumab), Briumvi (ublituximab), Escalation Therapies Group, Betaseron (beta interferon), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Extavia (beta interferon), Gilenya (fingolimod), Glatopa (glatiramer acetate), Plegridy (beta interferon), Rebif (beta interferon), Tecfidera (dimethyl fumarate), Avonex (beta interferon), Mavenclad (cladribine), Mayzent (siponimod), Vumerity (diroximel fumarate), Zeposia (ozanimod), Bafiertam (monomethyl fumarate), Ponvory (ponesimod)
The Cleveland Clinic, University of Nottingham
Multiple Sclerosis, Relapsing-Remitting
07/27
09/30
ACTRN12605000769684: An Open-label, Multicenter, Extension Study to Evaluate the Safety and Tolerability of Natalizumab Following Re-Initiation of Dosing in Multiple Sclerosis Subjects Who Have Completed Study C-1801 or C-1802 and a Dosing Suspension Safety Evaluation

Not yet recruiting
3/4
900
 
Biogen Idec, Biogen Idec, Elan Pharmaceuticals
Multiple Sclerosis
 
 
ACTRN12616000617460: What is the safety and effectiveness, acceptability and cost of flexible delivery of natalizumab (Tysabri (Registered Trademark)) by nurses for people with multiple sclerosis?

Active, not recruiting
3
50
 
Dr Janakan Ravindran, Biogen Australia and New Zealand
relapsing-remitting multiple sclerosis (MS)
 
 
2018-001292-21: Disease modifying therapies withdrawal in inactive Secondary Progressive Multiple Sclerosis patients older than 50 years Arrêt des traitements de fond à visée immunologique chez les patients de plus de 50 ans ayant une sclérose en plaques secondairement progressive

Not yet recruiting
3
250
Europe
AVONEX, BETAFERON, EXTAVIA, REBIF, PLEDIGRY, COPAXONE, AUBAGIO, TECFIDERA, GILENYA, TYSABRI, IMUREL, NOVATREX, CELLCEPT, ENDOXAN, L03 AB 08, Concentrate for solution for injection, Powder for solution for injection, Solution for injection, Solution for injection in pre-filled syringe, Tablet, Capsule, Concentrate for solution for infusion
CHU de Rennes, CHU de Rennes
Secondary Progressive Multiple Sclerosis Sclérose en plaques secondairement progressive, Secondary Progressive Multiple Sclerosis Sclérose en plaques secondairement progressive, Diseases [C] - Nervous System Diseases [C10]
 
 
NOVA, NCT03689972 / 2018-002145-11: A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration

Completed
3
585
Europe, Canada, US, RoW
Natalizumab, BG00002
Biogen
Multiple Sclerosis, Relapsing-Remitting
01/23
07/23
NCT05265728: A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis

Terminated
3
21
Japan
Natalizumab, BG00002
Biogen
Multiple Sclerosis, Relapsing-Remitting
01/24
05/24
BEAT-MS, NCT04047628: Best Available Therapy Versus Autologous Hematopoetic Stem Cell Transplant for Multiple Sclerosis

Recruiting
3
156
US
Autologous Hematopoietic Stem Cell Transplantation, AHSCT, Best Available Therapy (BAT), natalizumab (Tysabri®), alemtuzumab (Campath®, Lemtrada®), ocrelizumab (Ocrevus®), rituximab (Rituxan®), cladribine (Mavenclad®), ofatumumab (Kesimpta®), ublituximab (BRIUMVI™)
National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network (ITN), Blood and Marrow Transplant Clinical Trials Network, PPD DEVELOPMENT, LP, Rho Federal Systems Division, Inc.
Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
10/26
10/29
MIST, NCT03133403 / 2012-004165-41: Hematopoietic Stem Cell Therapy for Inflammatory Multiple Sclerosis Failing Alternate Approved Therapy

Recruiting
2/3
5
Europe
Tecfidera (BG12), Gilenya, fingolimod, Tysabri®, natalizumab, Avonex/Betaseron/Copaxone/Rebif, (Avonex®, Betaseron®, Copaxone®, Rebif®), Hematopoietic stem cell transplantation (HSCT)
Sheffield Teaching Hospitals NHS Foundation Trust
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
12/21
12/21
2010-023560-40: Blood stem cell transplantation for patients with relapsiong-remitting multiple sclerosis, in whom standard treatment has failed. Blodstamcellstransplantation för patienter med skovvis förlöpande MS (multipel sklerosis), där standardbehandling givit otillräcklig effekt.

Ongoing
2
120
Europe
, Powder for solution for injection, Powder for infusion*, Solution for injection, Powder and solvent for dispersion for injection, Tysabri, Sendoxan, Thymoglobuline, Neupogen, Solu-Medrol
Uppsala l�ns landsting
Relapsing-remitting multiple sclerosis
 
 
2014-000675-13: Natalizumab (Tysabri®) for the treatment of anti-Hu associated paraneoplastic neurological syndromes Natalizumab (Tysabri®) voor de behandeling van paraneoplastische neurologische syndromen met anti-Hu antistoffen

Ongoing
2
20
Europe
Tysabri (natalizumab), Concentrate and solvent for solution for infusion, Tysabri
Erasmus University Medical Center, Biogen Idec International B.V.
Anti-Hu associated paraneoplastic neurological syndromes, Anti-Hu associated paraneoplastic neurological syndromes, Diseases [C] - Immune System Diseases [C20]
 
 
2019-003127-38: Research on the effect of add-on high dosage simvastatin treatment on progression in MS patients treated with ocrelizumab and natalizumab. Onderzoek naar het effect van het toevoegen van hoge dosis simvastatine op progressie van MS patiënten die behandeld worden met ocrelizumab en natalizumab.

Not yet recruiting
2
100
Europe
Simvastatin, Tablet
VUmc Neurology Department, Stichting MS Research
Multiple sclerosis Multiple sclerose, Multiple sclerosis Multiple sclerose, Diseases [C] - Nervous System Diseases [C10]
 
 
2022-002654-95: No Evidence Of Disease Activity After Autologous Haematopoietic Stem Cell Transplantation In Aggressive Multiple Sclerosis Nessuna evidenza di attività della malattia dopo trapianto autologo di cellule staminali ematopoietiche nella Sclerosi Multipla aggressiva

Not yet recruiting
2
90
Europe
OCREVUS, Kesimpta 20 mg soluzione iniettabile, TYSABRI, LEMTRADA, Non disponibile, Solution for injection, Powder for concentrate for solution for infusion, Powder and solvent for concentrate for solution for infusion, Concentrate for solution for infusion, Powder and solvent for solution for injection, Powder for solution for injection, OCREVUS, Kesimpta, TYSABRI, LEMTRADA
FONDAZIONE ITALIANA SCLEROSI MULTIPLA ONLUS, Fondazione Italiana Sclerosi Multipla
Relapsing Remitting Multiple Sclerosis Sclerosi multipla recidivante remittente, A type of MS where you have relapses (symptoms getting worse) followed by recovery (that's when it's “remitting”) Forma di Sclerosi Multipla nella quale in cui si hanno ricadute (sintomi che peggiorano) seguite da guarigione (le remissioni)., Diseases [C] - Nervous System Diseases [C10]
 
 
NCT05418010: Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS)

Suspended
2
40
Europe
Tysabri Injectable Product, Natalizumab, Placebo
Queen Mary University of London, Biogen, UCL Queen Square Institute of Neurology, Moorfields Eye Hospital NHS Foundation Trust, Barts & The London NHS Trust
Multiple Sclerosis, Clinically Isolated Syndrome of Demyelination
01/28
01/28
2008-005871-92: En fas 1 studie av effekt av Tysabri (natalizumab), en IgG4 humaniserad monoklonal antikropp specifik mot VLA-4 (integrin alfa-4), administrerad som infusion 1 gång/månad under 3 månader hos patienter med kronisk idiopatisk trombocytopen purpura (ITP).

Ongoing
1/2
20
Europe
Tysabri, Tysabri, Tysabri
Sahlgrenska University Hospital
Chronic idiopathic thrombocytopenic purpura (ITP)
 
 
NCT03811886: Natalizumab in Recurrent, Refractory or Progressive Pulmonary Metastatic Osteosarcoma

Withdrawn
1/2
20
US
Natalizumab, Tysabri
Case Comprehensive Cancer Center
Pulmonary Metastatic Osteosarcoma (pOS)
12/25
10/26
NCT03093064: Inflammatory Response In Schizophrenia

Completed
1
66
Europe
Natalizumab, Tysabri, Placebo: normal saline
King's College London, South London and Maudsley NHS Foundation Trust
Schizophrenia
06/23
08/23
NCT05618301: Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD)

Active, not recruiting
1
10
US
Motixafortide, BL-8040, Natalizumab, Tysabri, Leukapheresis
Washington University School of Medicine, BioLineRx, Ltd., Biogen
Sickle Cell Disease
06/25
06/25
NCT06705608: Examining the Risk of Skin Cancer in Multiple Sclerosis Patients Using Fingolimod: a Population-Based Study

Completed
N/A
4000
NA
Fingolimod, Natalizumab, Dimethyl fumarate (DMF), Alemtuzumab, Teriflunomide
University of British Columbia
Multiple Sclerosis, Skin Cancer, Skin Cancer Melanoma, Skin Cancers - Basal Cell Carcinoma, Skin Cancer, Squamous Cell, Multiple Sclerosis (MS) - Relapsing-remitting
12/20
12/20
CPE, NCT05762003: Czech Pharmaco-epidemiological Study on Disease Modifying Drugs

Completed
N/A
17478
RoW
interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab
IMPULS Endowment Fund
Multiple Sclerosis
12/21
12/21
NCT04964700: Analysis of MS Patients Who Have Had Greater Than 60 Infusions of Natalizumab

Active, not recruiting
N/A
42
US
Natalizumab, Tysabri
Multiple Sclerosis Center of Northeastern New York
Multiple Sclerosis
04/22
06/22
COMBAT-MS, NCT03193866 / 2016-003587-39: COMparison Between All immunoTherapies for Multiple Sclerosis.

Completed
N/A
3526
Europe
Rituximab, Natalizumab, Fingolimod, Alemtuzumab, Interferon-beta, Glatiramer acetate, Dimethyl Fumarate
Karolinska Institutet, Patient-Centered Outcomes Research Institute, Kaiser Foundation Research Institute
Relapsing-remitting Multiple Sclerosis
03/22
03/22
NCT05627271: The 'Wearing Off' Effect of DMT

Completed
N/A
39
Europe
ocrelizumab, Ocrevus, natalizumab, Tysabri, ofatumumab, Kesimpta
Novartis Pharmaceuticals
Multiple Sclerosis
04/23
04/23
TYPIFI, NCT04832399: Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants

Completed
N/A
60
Europe
Natalizumab, Tysabri, BG00002
Biogen
Relapsing Remitting Multiple Sclerosis
10/23
10/23
NCT04565431: Examining Effects of Tysabri on Cognitive Fatigue Using fMRI

Recruiting
N/A
25
US
Tysabri
Kessler Foundation, St. Barnabas Medical Center
Multiple Sclerosis, Relapsing-Remitting
12/24
12/24
NCT05304520: A Study for Tysabri Participant Preference

Completed
N/A
318
Europe
Natalizumab
Biogen
Relapsing-Remitting Multiple Sclerosis (RRMS)
04/24
04/24
BABYZUMAB-2, NCT05209815: Safety of Exposure to Natalizumab During Pregnancy

Completed
N/A
68
Europe, RoW
Questionnaire
University Hospital, Bordeaux, Biogen
Multiple Sclerosis
12/23
12/23
NCT03399981: Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries

Completed
N/A
80327
US
Tysabri, Natalizumab BG00002
Biogen
Progressive Multifocal Leukoencephalopathy
12/23
12/23
Tys at Home, NCT04777539: Comparing the Safety and Benefit of Natalizumab (Tysabri®) At-home Infusion vs At-hospital Infusion in Multiple Sclerosis

Active, not recruiting
N/A
279
Europe
At-home natalizumab treated MS patient
Nantes University Hospital, Rennes University Hospital
Multiple Sclerosis (MS)
11/24
05/25
SATURATE-MS, NCT05701423: A Study of End of Dose Phenomena in Subcutaneous Natalizumab Treated Multiple Sclerosis (MS) Participants

Terminated
N/A
34
Europe
Natalizumab, Tysabri
Biogen
Multiple Sclerosis
07/24
07/24
NCT05925049: A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)

Active, not recruiting
N/A
400
US
Natalizumab, Tysabri
Biogen
Multiple Sclerosis
12/25
12/25
NCT05236777: TOPIK Study: A Study to Report Progressive Multifocal Leukoencephalopathy and Other Serious Opportunistic Infections in Natalizumab Treated Participants

Completed
N/A
675
RoW
Natalizumab, Tysabri
Biogen, ReMuS Registry
Multiple Sclerosis
04/25
04/25
TREAT-MS, NCT03500328: Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial

Active, not recruiting
N/A
900
US
Natalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq, Tysabri, Lemtrada, Ocrevus, Rituxan/Riabni/Truxima/Ruxience, Mavenclad, Kesimpta, Briumvi, Ocrevus Zunovo, Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod, Copaxone, Glatopa, Avonex, Betaseron, Extavia, Rebif, Plegridy, Aubagio, Tecfidera, Vumerity, Bafiertam, Gilenya, Mayzent, Zeposia, Ponvory, Tascenso
Johns Hopkins University, Patient-Centered Outcomes Research Institute, National Multiple Sclerosis Society
Multiple Sclerosis, Relapsing-Remitting
08/26
08/26
NCT00493298: Tysabri Observational Program

Checkmark TOP
Jun 2014 - Jun 2014: TOP
Checkmark ACTRIMS 2014: MS (TOP)
Jun 2014 - Jun 2014: ACTRIMS 2014: MS (TOP)
Checkmark EFNS-ENS 2014: MS (TOP)
More
Completed
N/A
6620
Europe, Canada, RoW
Tysabri, BG00002, natalizumab
Biogen
Relapsing-Remitting Multiple Sclerosis
11/23
11/23
NCT05688436: A Study to Assess Pregnancy Outcomes in Women Exposed to Diroximel Fumarate

Recruiting
N/A
1178
US
Diroximel Fumarate, VUMERITY, BIIB098, Alemtuzumab, Fingolimod, Glatiramer acetate, Interferon beta, Natalizumab, Tysabri, BG00002, Ocrelizumab, Ofatumumab, Ozanimod, Peginterferon beta-1a, Ponesimod, Siponimod
Biogen
Multiple Sclerosis
01/31
01/31
NCT05658497: Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)

Recruiting
N/A
908
Europe, US
Diroximel Fumarate, VUMERITY, BIIB098, Avonex, BG9418, interferon beta-1a, Tysabri, Natalizumab, BG00002, Dimethyl Fumarate, Tecfidera, DMF, BG00012
Biogen
Multiple Sclerosis
07/32
07/32
Qinprezo (vosaroxin) / Denovo
BIG-1, NCT02416388: Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR

Recruiting
2/3
3100
Europe
Idarubicin, Daunorubicin, HD Cytarabine, Cyclosporine, Methotrexate, Mycophenolic acid (MPA), vosaroxin, ID cytarabine, Dexamethasone, Venetoclax
University Hospital, Angers
Acute Myeloid Leukemia (AML)
07/25
01/32
VITAL, NCT02658487: Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia

Completed
2
42
US
Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosar-U, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Vosaroxin, AG-7352, SNS-595, SPC 595, Voreloxin
Vanderbilt-Ingram Cancer Center, National Cancer Institute (NCI)
Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia With Multilineage Dysplasia, Myeloid Sarcoma, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia, Therapy-Related Myelodysplastic Syndrome
04/19
09/24
2015-004066-28: A Phase II Study with a Safety Run-in Phase Evaluating Vosaroxin With Azacitidine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia and Intermediate/Adverse Genetic Risk or Myelodysplastic Syndrome with Excess Blasts-2 (MDS-EB-2) - AMLSG 24-15 Studie mit einem Dosisfindungsteil gefolgt von einem Phase II-Teil zu Vosaroxin in Kombination mit Azacitidin bei Patienten mit akuter myeloischer Leukämie und intermediärem bzw. ungünstigem genetischem Risiko oder myelodysplastischen Syndrom mit Exzess von Blasten (MDS-EB-2) (AMLSG 24-15)

Not yet recruiting
2
168
Europe
Azacitidine, Vosaroxin, not applicalbe, Powder for injection, Injection, Vidaza
University Hospital Ulm, SUNESIS PHARMACEUTICALS, INC, University Hospital Ulm
Patients with confirmed diagnosis of acute myeloid leukemia (WHO 2016) and intermediate or adverse genetic risk (according to 2017 ELN recommendations); or patients with myelodysplastic syndrome with excess blasts-2 (MDS-EB-2) Patienten mit bestätigter Diagnose einer akuten myeloischen Leukämie (WHO 2016) und intermediärem oder ungünstigem genetischem Risiko (entsprechend den ELN Empfehlungen 2017); oder Patienten mit myelodysplastischem Syndrom mit Exzess von Blasten (MDS-EB-2), Patients with Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with Excess Blasts-2 (MDS-EB-2) Patienten mit Neu diagnostizierte akute myeloische Leukämie oder myelodysplastisches Syndrom mit Exzess von Blasten (MDS-EB-2), Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT01913951: Vosaroxin and Azacitidine in Treating Patients With Myelodysplastic Syndromes

Checkmark For vosaroxin and azacitidine combination trial in myelodysplastic syndrome at EHA 2017
Jun 2017 - Jun 2017: For vosaroxin and azacitidine combination trial in myelodysplastic syndrome at EHA 2017
Checkmark ASH 2015
Dec 2015 - Dec 2015: ASH 2015
Completed
1
35
US
vosaroxin, voreloxin, Azacitidine, Vidaza, Ladakamycin
Washington University School of Medicine, Sunesis Pharmaceuticals
Myelodysplastic Syndromes
12/16
04/24
ampreloxetine (TD-9855) / Theravance Biopharma
CYPRESS, NCT05696717: Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy

Recruiting
3
102
Europe, Canada, US, RoW
Ampreloxetine, TD-9855, Placebo
Theravance Biopharma
Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy
12/24
01/27
Spinraza (nusinersen) / Biogen
2020-005180-30: Etude des effets fonctionnels du nusinersen chez des personnes amyotrophiques spinaux adultes par déficit génétique 5q de type 2 ou 3 : étude expérimentale en cas unique en lignes de base multiples à travers les sujets, multicentrique, randomisée, en simple aveugle Etude des effets fonctionnels du nusinersen chez des personnes amyotrophiques spinaux adultes par déficit génétique 5q de type 2 ou 3 : étude expérimentale en cas unique en lignes de base multiples à travers les sujets, multicentrique, randomisée, en simple aveugle

Not yet recruiting
4
24
Europe
Solution for injection, Spinraza
Centre Hospitalier Universitaire de Reims, Centre Hospitalier Universitaire de Reims
tout patient éligible (patient 5q SMA type 2 ou 3 pour lequel le traitement par nusinersen a été validé par le centre de référence et de compétence des maladies neuromusculaires et un neurologue). Une information concernant les objectifs et les modalités de la recherche lui sera donnée à l’aide de la note d’information. Si le patient accepte de participer à la recherche, il devra signer le consentement de participation. tout patient éligible (patient 5q SMA type 2 ou 3 pour lequel le traitement par nusinersen a été validé par le centre de référence et de compétence des maladies neuromusculaires et un neurologue). Une information concernant les objectifs et les modalités de la recherche lui sera donnée à l’aide de la note d’information. Si le patient accepte de participer à la recherche, il devra signer le consentement de participation., tout patient éligible (patient 5q SMA type 2 ou 3 pour lequel le traitement par nusinersen a été validé par le centre de référence et de compétence des maladies neuromusculaires et un neurologue) tout patient éligible (patient 5q SMA type 2 ou 3 pour lequel le traitement par nusinersen a été validé par le centre de référence et de compétence des maladies neuromusculaires et un neurologue), Diseases [C] - Musculoskeletal Diseases [C05]
 
 
2019-005007-40: Natural history study in adult patients with SMA types 2-3-4 and Role of neurodegenerative and neuro-inflammatory biomarkers in SMA adults treated with nusinersen. Studie van het natuurlijk ziekteverloop bij volwassen patiënten met spinale spieratrofie (SMA) en de rol van biomerkers bij SMA patiënten die met nusinersen behandeld worden.

Not yet recruiting
4
19
Europe
Solution for injection, Spinraza
University Hospitals Leuven, Biogen
Adult patients with spinal muscular atrophy (SMA) type 2, type 3, or type 4, spinal muscular atrophy (SMA), Diseases [C] - Nervous System Diseases [C10]
 
 
RESPOND, NCT04488133 / 2020-003492-18: A Study to Learn About the Effect of Nusinersen (BIIB058) Given as Injections to Children With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec

Active, not recruiting
4
46
Europe, US, RoW
Nusinersen, ISIS 396443, BIIB058, Spinraza
Biogen
Muscular Atrophy, Spinal
10/25
10/25
RISE, NCT05522361: Risdiplam in Patients With Spinal Muscular Atrophy Previously Treated With Nusinersen

Active, not recruiting
4
10
US
Risdiplam
Clinic for Special Children, Genentech, Inc.
Spinal Muscular Atrophy
12/25
06/26
2021-006709-31: Phase IIIb, open-label, multi-center study to evaluate safety, tolerability and efficacy study of OAV101 administered intrathecally to participants with spinal muscular atrophy (SMA) who have discontinued treatment with nusinersen or risdiplam

Ongoing
3
28
Europe
OAV101, OAV101, Solution for injection, Zolgensma
Novartis Pharma AG, Novartis Pharma AG
Spinal Muscular Atrophy, Spinal Muscular Atrophy, Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
 
 
SHINE, NCT02594124 / 2015-001870-16: A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies

Completed
3
292
Europe, Canada, Japan, US, RoW
nusinersen, ISIS 396443, Spinraza, BIIB058, IONIS SMN Rx, ISIS SMNRx
Biogen
Spinal Muscular Atrophy
08/23
08/23
DEVOTE, NCT04089566 / 2019-002663-10: Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy

Completed
3
145
Europe, Canada, Japan, US, RoW
Nusinersen, BIIB058
Biogen
Muscular Atrophy, Spinal
02/24
05/24
SAPPHIRE, NCT05156320 / 2021-005314-34: Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam

Completed
3
188
Europe, US
Apitegromab, SRK-015, Placebo
Scholar Rock, Inc.
Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3, Spinal Muscular Atrophy Type 2, SMA, Neuromuscular Diseases, Muscular Atrophy, Atrophy, Muscular Atrophy, Spinal, Neuromuscular Manifestations, Anti-myostatin
12/24
12/24
STRENGTH, NCT05386680: Phase IIIb, Open-label, Multi-center Study to Evaluate Safety, Tolerability and Efficacy of OAV101 Administered Intrathecally to Participants With SMA Who Discontinued Treatment With Nusinersen or Risdiplam

Completed
3
27
Europe, Canada, Japan, US, RoW
OAV101, AVXS-101, Zolgensma
Novartis Pharmaceuticals
Spinal Muscular Atrophy
11/24
11/24
ONWARD, NCT04729907 / 2020-004708-32: A Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Took Part in an Earlier Nusinersen Trial

Active, not recruiting
3
115
Europe, Canada, Japan, US, RoW
Nusinersen, BIIB058, Spinraza
Biogen, Biogen Idec Research Limited
Muscular Atrophy, Spinal
07/26
07/26
ASCEND, NCT05067790 / 2021-001294-23: A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam

Active, not recruiting
3
45
Europe, Japan, US, RoW
Nusinersen, BIIB058, Spinraza
Biogen
Spinal Muscular Atrophy
06/27
06/27
NURTURE, NCT02386553 / 2014-002098-12: A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy

Completed
2
25
Europe, Canada, US, RoW
Nusinersen, ISIS 396443, BIIB058, ISIS SMNRx, Spinraza
Biogen
Spinal Muscular Atrophy
12/24
12/24
OPAL, NCT07047144: A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy

Not yet recruiting
2
52
NA
Apitegromab, SRK-015, Nusinersen, Spinraza, Risdiplam, Evrysdi
Scholar Rock, Inc.
Spinal Muscular Atrophy, SMA, Spinal Muscular Atrophy Type 2, Spinal Muscular Atrophy Type 3, Neuromuscular Manifestations, Anti-myostatin
11/28
03/29
ChiCTR2200063672: EC50 of propofol with target controlled infusion for intrathecal injection of Nusinersen in children with spinal muscular atrophy

Not yet recruiting
1
30
 
Target controlled infusion of propofol for intravenous anesthesia
The First Affiliated Hospital of Fujian Medical University; The First Affiliated Hospital of Fujian Medical University, self-raised
Spinal muscular atrophy
 
 
PIERRE-PK, NCT06555419: A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy

Recruiting
1
58
Europe, US
Nusinersen, BIIB058, ThecaFlex DRx System
Biogen, Alcyone Therapeutics, Inc
Muscular Atrophy, Spinal
05/26
05/26
NCT02865109: Expanded Access Program (EAP) for Nusinersen in Participants With Infantile-onset (Consistent With Type 1) Spinal Muscular Atrophy (SMA)

No Longer Available
N/A
RoW
Nusinersen, ISIS 396443, BIIB058, Spinraza
Biogen
Infantile-onset Spinal Muscular Atrophy
 
 
NCT03878030: Effect of Nusinersen on Adults With Spinal Muscular Atrophy

Completed
N/A
12
US
nusinersen, Spinraza
Northwell Health
Adult Spinal Muscular Atrophy
07/21
07/21
NCT04674618: Ultrasound-assisted vs Landmark Based Intrathecal Administration of Nusinersen

Completed
N/A
58
Europe
US-assisted nusinersen administration
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Muscular Atrophy, Spinal, Ultrasound
12/21
12/23
 

Download Options